Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
AssigneesAstex Therapeutics Limited, The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology Limited
InventorsSteven John Woodhead, David Charles Rees, Kyla Merriom Grimshaw
Life of this patent
Estimating the term…
Abstract
The invention provides a composition comprising (S)2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, wherein the composition is either substantially free of (R)2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or the composition contains a mixture of the (S) and (R) enantiomers in which the (S) enantiomer predominates. Also provided are processes for the preparation of the (S)2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, novel process intermediates and methods for making the novel process intermediates.
Claims8
A method of modulating a cellular process by inhibiting the activity of a ROCK kinase comprising administering a therapeutically effective amount of a composition comprising (S)2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol in the form of a hydrochloride salt, wherein at least 98% of 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol hydrochloride salt in the composition is in the S-enantiomeric form.
A method for inhibiting ROCK kinase;
- which method comprises bringing the ROCK kinase in a cellular environment, into contact with a composition comprising (S)2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol in the form of a hydrochloride salt, wherein at least 98% of 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol hydrochloride salt in the composition is in the S-enantiomeric form.
Dependencies are inferred from the claim text.